key: cord-0924527-kzwqn4kc
authors: Börger, Verena; Weiss, Daniel J.; Anderson, Johnathon D.; Borràs, Francesc E.; Bussolati, Benedetta; Carter, David R.F.; Dominici, Massimo; Falcón-Pérez, Juan M.; Gimona, Mario; Hill, Andrew F.; Hoffman, Andrew M.; de Kleijn, Dominique; Levine, Bruce L.; Lim, Rebecca; Lötvall, Jan; Mitsialis, S. Alex; Monguió-Tortajada, Marta; Muraca, Maurizio; Nieuwland, Rienk; Nowocin, Anna; O'Driscoll, Lorraine; Ortiz, Luis A.; Phinney, Donald G; Reischl, Ilona; Rohde, Eva; Sanzenbacher, Ralf; Théry, Clotilde; Toh, Wei Seong; Witwer, Kenneth W.; Lim, Sai Kiang; Giebel, Bernd
title: ISEV and ISCT statement on EVs from MSCs and other cells: considerations for potential therapeutic agents to suppress COVID-19
date: 2020-05-16
journal: Cytotherapy
DOI: 10.1016/j.jcyt.2020.05.002
sha: 33d88801dce47fcb356fb3112e1a623ecc281f75
doc_id: 924527
cord_uid: kzwqn4kc

nan

other cell sources as treatments for Research and trials in this area are encouraged. However, ISEV and ISCT do not currently endorse the use of EVs or exosomes for any purpose in COVID-19, including but not limited to reducing cytokine storm, exerting regenerative effects, or delivering drugs, pending the generation of appropriate manufacturing and quality control provisions, pre-clinical safety and efficacy data, rational clinical trial design, and proper regulatory oversight.

First described in December 2019, the severe acute respiratory syndrome associated with coronavirus disease 19 (COVID-19) quickly evolved into a pandemic with severe and increasing worldwide morbidity and mortality. Although most infected patients have mild to moderate symptoms or are even asymptomatic, older patients or those with existing chronic diseases are at greater risk of developing serious complications such as pneumonia or multiple organ failures. COVID-19 respiratory infection is marked by dysregulated immune responses leading to significant respiratory pathology as well as increased probabilities for multi-organ pathologies. While the inflammatory pathways are still being elucidated, notable components include increased circulating levels of pro-inflammatory cytokines and other mediators including interleukin-6 (IL-6), interleukin-1β (IL-1β), induced protein 10 (IP10) and monocyte chemoattractant protein-1 (MCP-1) Diao et al., 2020; . There are also significant alterations in circulating inflammatory cell populations with initial lymphocytosis followed by severe lymphopenia, with increased ratios of helper to regulatory T cells Diao et al., 2020; Qin et al., 2020) . Since dysregulated immune responses and the cytokine storm are triggers for development of acute respiratory distress syndrome (ARDS), an increasing effort and current clinical trials are focused on immune therapeutic approaches such as IL-1 blockade (anakinra), IL-6 receptor blockade (tocilizumab) or Janus kinase (JAK) inhibition (Mehta et al., 2020) . In parallel, there are a rapidly increasing number of cell-based therapy investigations, mostly utilizing mesenchymal stromal cells (MSCs) (Khoury et al., 2020a) . These are based on supporting pre-clinical data for use of MSCs delivered either systemically or intratracheally in pre-clinical models of acute lung injuries and on demonstration of safety of systemic MSC administration in recent trials for ARDS resulting from other etiologies (Laffey and Matthay, 2017; Matthay et al., 2019) .

Among the cell-based therapy investigations for COVID-19, some registered clinical trials aim to utilize extracellular vesicles (EVs) prepared from MSC conditioned media rather than the cells themselves. MSC-EVs will be administered intravenously (ChiCTR2000030484), or by inhalation (NCT04276987, ChiCTR2000030261). The rationale for these approaches is based on a relatively small but growing number of investigations in pre-clinical lung injury and sepsis models, in which MSC-EV preparations were described as safe and effective, if not more effective than their parent cells (Mahida et al., 2020; Worthington and Hagood, 2020) . The approach is further supported by a growing body of literature on the therapeutic potential and mechanisms of EVs in a wide range of diseases, including recent positive results in a steroid-refractory Graft-versus-Host Disease (GvHD) patient treated with MSC-EVs, and in a single centre, randomized, placebo-controlled phase II/III clinical pilot study on chronic kidney disease (CDK) patients treated with MSC-EVs (Kordelas et al., 2014; Nassar et al., 2016) .

The mechanisms, by which EVs exert their beneficial effects, as well as their site(s) of action, remain incompletely understood. Nonetheless, effects observed in a range of pre-clinical non-COVID-19 model systems suggest that they may also have efficacy against COVID-19. Notably, in E. coli induced pneumonia mouse models, MSC-EV administration was found to enhance phagocytosis of bacteria (Hao et al., 2019; Monsel et al., 2015) . In a pig model MSC-EVs were shown to attenuate influenza virus-induced acute lung injury, amongst others by inhibiting influenza virus replication (Khatri et al., 2018) . Diseaseattenuating effects on inflammatory immune responses following MSC-EV administration have also been observed in other disease models (Börger et al., 2017) . In an ischemic stroke model, for example, systemic MSC-EV administration reduced stroke-induced lymphopenia and pro-inflammatory immune responses in the brain and periphery, resulting in overall improvement of disease symptoms (Doeppner et al., 2015; Wang et al., 2020) . These preliminary observations support MSC-EV administration as a potential treatment option for COVID-19.

However, the specific scientific rationale for MSC-EV and other EV administration to COVID-19 patients needs to be better understood and justified. For example, MSC-EVs do not necessarily suppress immune responses, but rather modulate them. Specifically, they seem to moderate acute immune responses towards regulatory responses, with the latter inducing tolerance and restoring homeostasis (Giebel and Hermann, Zhang et al., 2018; Zhang et al., 2014) . While tolerance induction in GvHD and other non-infectious diseases may be beneficial, it might also have severe adverse effects in the presence of replicating pathogens.

Although influenza and E. coli infections were attenuated in selected models (Hao et al., 2019; Khatri et al., 2018; Monsel et al., 2015) , other viruses and bacteria might conceivably expand in uncontrolled manners in induced tolerogenic environments.

A number of additional issues should be considered before administering MSC-EVs to COVID-19 patients. These include the source of MSC-EVs. MSCs are a heterogeneous cell entity that can be obtained from different tissues. Even if derived from the same tissues, they may display interindividual and possibly clone specific functional differences (Phinney, 2012; Phinney et al., 1999; Radtke et al., 2016; Vogel et al., 2003) . Indeed, side-by-side comparison of four MSC-EV preparations harvested from the conditioned media of different donor-derived bone marrow MSCs demonstrated significant variations in cytokine content (Kordelas et al., 2014) . Whether this correlates with therapeutic potency is not yet clear; however, in the example of the ischemic stroke model, it was demonstrated that MSC-EV preparations with comparable particle and protein contents can significantly differ in potency.

While some preparations effectively suppressed stroke symptoms, others failed to exert therapeutic activities . Furthermore, in an acute lung injury model, EVs from young but not from aged MSCs alleviated LPS-induced acute lung injury .

Potentially, heterogeneity of EV potency due to different sources, preparations, aging, and other factors could be resolved by generating immortalized clonal MSC lines that could be rigorously tested for EV production and potency (Chen et al., 2011) . Still, apart from their immunomodulatory capabilities, MSC-EVs apparently also control additional biological processes, some with approved therapeutic functions (Arslan et al., 2013) , and others that might trigger unforeseen side effects. Just recently, it was found that adipose-derived MSC-EVs had higher thrombogenic activities than bone-marrow-derived MSC-EVs (Chance et al., Silachev et al., 2019) . Thus, the source of parental cells might increase thrombosis risks. Coupled to the finding that activation of complement pathways and an associated procoagulant state seem to result in catastrophic microvascular injury syndrome in a proportion of severe COVID-19 cases (Magro et al., 2020) , MSC-EV administration could even be counterproductive in COVID-19.

To this end, it is imperative that stringent "identity" and "potency" parameters are defined and potential side effects addressed before MSC-EV or other EV preparations are released for therapeutic applications (Lener et al., 2015; Reiner et al., 2017; Witwer et al., 2019) . To date, many groups use in-house MSC-EV manufacturing and characterization strategies, mainly for preclinical studies (Börger et al., 2017) . Protocols fulfilling good manufacturing practice (GMP) criteria are sparse, and just a few have been published Pachler et al., 2017; Rohde et al., 2019) . For product candidates, studies focusing on safety and clinical pharmacology need to be performed. Results of such studies are mandatory to provide guidance for adjustment of manufacturing, storage, dosing, and administration of EVbased therapeutics in specific target diseases.

We would like to refer to a recent statement by ISCT on the use of MSCs in COVID-19 (Khoury et al., 2020b) 1, 2020) . 5 COVID-19 EMA pandemic Task Force (COVID-ETF): "to help EU Member States and the European Commission to take quick and coordinated regulatory action on the development, authorisation and safety monitoring of treatments and vaccines intended for the treatment and prevention of COVID-19." https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/emas-governance-during-covid-19-pandemic#covid-19-ema-pandemic-task-force-section 6 https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/guidance-medicine-developers-companies-covid-19 7 https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-10/guidanceclinicaltrials_covid19_en.pdf 8 https://www.gov.uk/guidance/mhra-regulatory-flexibilities-resulting-from-coronavirus-covid-19#clinical-trials

In conclusion, to mitigate the risk of potential of life-threatening side effects, ISCT and ISEV strongly urge that the potential benefits and risks in the use of MSC-EVs for COVID-19 be weighed carefully against available pre-clinical data in relevant animal models and clinical data from relevant MSC clinical trials, and that any use of EVs be carefully evaluated through rational clinical trial design, employing well-characterized EV preparations produced under strict GMP conditions and under the proper regulatory oversight.

JDA: Co-founder of an exosome therapeutics company called Somos Therapeutics, Inc. 

Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury

Mesenchymal Stem/Stromal Cell-Derived Extracellular Vesicles and Their Potential as Novel Immunomodulatory Therapeutic Agents

The effects of cell type and culture condition on the procoagulant activity of human mesenchymal stromal cell-derived extracellular vesicles

Clinical and immunological features of severe and moderate coronavirus disease 2019

Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCs

Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019 (COVID-19). medRxiv, 2020

Extracellular Vesicles Improve Post-Stroke Neuroregeneration and Prevent Postischemic Immunosuppression

Manufacturing of Human Extracellular Vesicle-Based Therapeutics for Clinical Use

Mesenchymal Stem Cell-Derived Extracellular Vesicles Decrease Lung Injury in Mice

Differential effects of extracellular vesicles from aging and young mesenchymal stem cells in acute lung injury

Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model

Current Status of Cell-Based Therapies for Respiratory Virus Infections: Applicability to COVID-19

Cell-Based Therapies for COVID-19: Proper Clinical Investigations are Essential

MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease

Fifty Years of Research in ARDS. Cell-based Therapy for Acute Respiratory Distress Syndrome. Biology and Potential Therapeutic Value

Applying extracellular vesicles based therapeutics in clinical trials -an ISEV position paper

Exosomes Released by Bone Marrow Mesenchymal Stem Cells Attenuate Lung Injury Induced by Intestinal Ischemia Reperfusion via the TLR4/NF-kappaB Pathway

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

Extracellular Vesicles: A New Frontier for Research in Acute Respiratory Distress Syndrome

Mesenchymal stromal cell exosomes prevent and revert experimental pulmonary fibrosis through modulation of monocyte phenotypes

Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial

COVID-19: consider cytokine storm syndromes and immunosuppression

Therapeutic Effects of Human Mesenchymal Stem Cell-derived Microvesicles in Severe Pneumonia in Mice

Mesenchymal Stromal Cells Modulate Macrophages in Clinically Relevant Lung Injury Models by Extracellular Vesicle Mitochondrial Transfer

Umbilical cord mesenchymal stem cells derived extracellular vesicles can safely ameliorate the progression of chronic kidney diseases

A Good Manufacturing Practice-grade standard protocol for exclusively human mesenchymal stromal cell-derived extracellular vesicles

Mesenchymal stromal cell-derived nanovesicles ameliorate bacterial outer membrane vesicleinduced sepsis via IL-10

Functional heterogeneity of mesenchymal stem cells: implications for cell therapy

Donor variation in the growth properties and osteogenic potential of human marrow stromal cells

Dysregulation of immune response in patients with COVID-19 in Wuhan

Human mesenchymal and murine stromal cells support human lympho-myeloid progenitor expansion but not maintenance of multipotent haematopoietic stem and progenitor cells

Concise Review: Developing Best-Practice Models for the Therapeutic Use of Extracellular Vesicles

Manufacturing and characterization of extracellular vesicles from umbilical cord-derived mesenchymal stromal cells for clinical testing

Effect of MSCs and MSC-Derived Extracellular Vesicles on Human Blood Coagulation. Cells 8

Extracellular Vesicles from Interferon-gamma-primed Human Umbilical Cord Mesenchymal Stromal Cells Reduce Escherichia coli-induced Acute Lung Injury in Rats

Heterogeneity among human bone marrow-derived mesenchymal stem cells and neural progenitor cells

Mesenchymal Stromal Cell-Derived Small Extracellular Vesicles Induce Ischemic Neuroprotection by Modulating Leukocytes and Specifically Neutrophils

Mesenchymal Stromal Cell Exosomes Ameliorate Experimental Bronchopulmonary Dysplasia and Restore Lung Function through Macrophage Immunomodulation

Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications

Therapeutic Use of Extracellular Vesicles for Acute and Chronic Lung Disease

Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome. medRxiv

Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice